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Abstract
Science can be seen as a sequential process where each new study augments
evidence to the existing knowledge. To have the best prospects to make an
impact in this process, a new study should be designed optimally taking into
account the previous studies and other prior information. We propose a formal
approach for the covariate prioritization, i.e., the decision about the covariates
to be measured in a new study. The decision criteria can be based on conditional
power, change of the p-value, change in lower confidence limit, Kullback-Leibler
divergence, Bayes factors, Bayesian false discovery rate or difference between
prior and posterior expectation. The criteria can be also used for decisions on
the sample size. As an illustration, we consider covariate prioritization based on
genome-wide association studies for C-reactive protein levels and make sugges-
tions on the genes to be studied further.
keywords: design; evidence-based medicine; meta-analysis; power; scientific method
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1 Introduction
The efficient allocation of resources is desirable in all areas of society, including re-
search. Statistical methods have frequently been applied to optimize the design in
experimental and observational studies. We extend the scope of optimality considera-
tions from a single study to the research as an ongoing cumulative process where each
new study augments evidence to the existing knowledge. Here optimality means that
the new study will increase our knowledge as much as possible. We consider covariate
prioritization, i.e., the decision which covariates should be measured in a new study
and introduce tools that may help to answer the question “What should be studied
or measured next?” The costs and the practical limitations are not directly examined
but the number of covariates in the new study is assumed to be restricted.
As a motivating example, we consider replication studies for genome wide associa-
tion studies (GWAS) (McCarthy et al., 2008; Johnson and O’Donnell, 2009) where the
aim is to find genes that are associated with a disease outcome or a phenotype. The
task is to select genes for an additional replication study on the basis of a published
meta-analysis of the original GWAS and earlier replication studies. Conceptually, genes
(or covariates in the general case) can be divided into three categories:
1. In category I, there is already convincing evidence that the covariate is an im-
portant predictor for the outcome. Further studies are not needed to increase
this evidence but there may still be good reasons to include the covariate in new
studies. For instance, known or suspected confounders should be included as well
as covariates needed to study interactions and subgroup effects.
2. In category II, the covariate potentially has an effect of clinical importance but
the sample sizes in the earlier studies are inadequate for making conclusive judge-
ments. Further studies could create new knowledge that will allow reclassify a
covariate in category II into category I or III.
3. In category III, the prior knowledge and existing studies show convincing evidence
of the absence of a clinically significant effect. New studies with affordable sample
sizes are not expected to change the conclusions.
The categorization involves some level of subjectivity because there are several ways to
quantify the limits between the categories. It is assumed that issues related to multiple
testing are taken into account.
We suggest that replication studies, i.e. studies where existing well-specified sci-
entific questions are considered, should concentrate on the covariates in category II.
We restrict ourselves to setups where the covariates are directly comparable and their
importance can be measured by the effect size. The evidence from the new study is
combined with the existing evidence using meta-analysis. In this setup, the scientific
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impact of a new study may be conceptually defined as a function of the importance
of the problem and the change in the knowledge due to the new study. The scientific
impact is high if the study creates a lot of new knowledge on a very important ques-
tion. If the problem is not important or the study creates only a small amount of new
knowledge, the scientific impact is low.
We study various approaches to the covariate prioritization in the design phase of
replication studies. According to our knowledge, the problem has not been consid-
ered systematically earlier. The closest related work by Nikolakopoulou et al. (2016)
considers the selection of study designs, treatments and sample sizes in a network meta-
analysis. Other related works are by Sutton et al. (2007) and Roloff et al. (2013) but
they consider only sample size determination, not covariate prioritization. The connec-
tions to meta-analysis, multi-stage study design and covariate selection in statistical
modeling are briefly discussed in the next.
There are only a few examples where meta-analysis has been used to guide the study
design. Sutton et al. (2007) used the results of a Bayesian meta-analysis as a start-
ing point and considered sample size determination for a new study using conditional
power in the updated meta-analysis as the design criterion. They found that condi-
tional power can be highly dependent on the statistical model used in meta-analysis
and even very large studies may have only a small impact on the population level es-
timates when there is a considerable heterogeneity between the studies. Roloff et al.
(2013) proposed a conceptually similar approach that optimizes conditional power in
the frequentist setup and avoids Markov Chain Monte Carlo (MCMC) computations.
The related questions include the sufficiency of the evidence from cumulative meta-
analyses (Ferreira et al., 2012; Langan et al., 2012; Wetterslev et al., 2008) and the
quantification of the additional sample size needed due to the study heterogeneity
(Wetterslev et al., 2009). Conditional power has been also used to inform the design of
future clinical trials in network meta-analysis (Nikolakopoulou et al., 2014). Recently,
Nikolakopoulou et al. (2016) proposed a methodology to prioritize further research tak-
ing into account the findings of a network meta-analysis model within the context of
total gain in precision. Methods to find out whether a meta-analysis should be updated
with the latest studies have been also proposed (Barrowman et al., 2003; Sutton et al.,
2009). From a different perspective, a decision theoretic framework for the adapta-
tion of health-care technologies has been proposed (Claxton et al., 2002, 2004). The
framework provides a rational way to compare the costs and benefits of additional data
collection with the cost of the uncertainty.
A study designed using the meta-analysis can be seen as a two-stage study where
the ‘first stage’ has already been published as a meta-analysis and we are planning
the ‘second stage’. An important difference is that in multi-stage studies, the new
measurements are made for individuals already in the study whereas in our situation,
completely new subjects are sampled for the new study. Similar setting is present in
the phase II futility study design of phase III clinical trials (Levin, 2005).
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Variable selection is a widely studied topic in statistical modeling. Commonly
used variable selection criteria: Bayesian information criterion (BIC) (Schwarz, 1978),
Akaike information criterion (AIC) (Akaike, 1974) and least absolute shrinkage and se-
lection operator (LASSO) (Tibshirani, 1996) are based on likelihood or individual level
data which we do not have available for the new study at the design phase. Differently
to model selection, our aim is to select the covariates before the new study is carried out.
In genetics, for instance, replication studies (Little et al., 2009; Sillanpa¨a¨ and Auranen,
2004; Karvanen et al., 2009) have been commonly used to confirm or discard the find-
ings from GWAS and linkage studies (Ott, 1999). However, the choice of the data
/ pedigree to replicate has been based on expert opinions and expected lod score
(Ott, 1999) thresholds instead of the explicit consideration of expected scientific im-
pact at marker level. Haplotype tagging single-nucleotide polymorphism (SNP) selec-
tion exercises operate at marker level but have different targets (Meng et al., 2003;
Lin and Altman, 2004).
The detailed definition of the problem is given in Section 2. In Section 3, seven
possible criteria for the covariate prioritization are presented. The formulation and use
of these criteria for this purpose has not been proposed earlier although their building
blocks may not be new (e.g., conditional power has been proposed for sample size
determination). The criteria are applied in practice in Section 4 where a meta-analysis
of GWAS for C-reactive protein (CRP) levels are considered from the viewpoint of
expected scientific impact. Conclusions are presented in Section 5.
2 Problem definition
2.1 Covariate prioritization in fixed and random effects meta-
analysis
Consider a parametric statistical model where regression coefficient βk, k = 1, . . . , K
describes the individual level effect of the covariate k on the outcome. A sequence
of studies is carried out and after each stage meta-analysis is applied to update our
knowledge on βk. The data collected at stage j is denoted by Dj and may comprise one
or more studies. Under the Bayesian framework, assume that all existing information
on βk after stage 1 can be expressed in the form of a distribution
βk|D1 ∼ N(µ1k, σ
2
1k), (1)
where µ1k and σ
2
1k are the expected value and the variance of βk. If the prior distribution
for βk before any data are collected is uninformative, the normality assumption can be
usually justified either directly or after a suitable transformation of the parameter.
After collecting new data in stage 2, the cumulative information on βk can be
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expressed in the form of a distribution
βk|D1, D2 ∼ N(µ2k, σ
2
2k), (2)
where D2 represents the data from stage 2 and µ2k and σ
2
2k are the expected value
and the variance of βk. In other words, the studies in stage 2 updated our knowledge
from N(µ1k, σ
2
1k) to N(µ2k, σ
2
2k). The scientific impact of this update consist of three
components: the improvement of the precision σ2
1k → σ
2
2k, the change of the mean
µ1k → µ2k and the clinical/practical importance of covariate k as a predictor. It is
assumed that the uncertainty on βk is only due to our lack of knowledge and the
variance will approach zero if more studies are conducted.
The problem of interest has three aspects:
1. How to measure the (realized) scientific impact after new study has been carried
out, i.e. when µ2k and σ
2
2k are known.
2. How to estimate the expected scientific impact before the new study, i.e. when
µ1k and σ
2
1k are known but µ2k and σ
2
2k are unknown.
3. How to use the expected scientific impact to guide covariate prioritization.
The problem formulation can be related to the meta-analysis in several ways. In
fixed effects meta-analysis, the studies are assumed to be homogeneous and βk repre-
sents the true effect common for all studies. An estimate from a single study differs
from βk only because of sampling error. It is assumed here that there is no publication
bias in the meta-analysis. The point estimates and standard errors from a frequentist
meta-analysis are interpreted in a Bayesian way (Schmid et al., 2004) by assuming the
expected value of distribution (1) equals the point estimate and the standard deviation
of distribution (1) equals the standard error. When estimating the expected scientific
impact before the new study, variance σ2
2k can be usually reliably approximated on
the basis of the variance σ2
1k and the planned sample size. Parameter µ2k cannot be
approximated in a similar manner but its expectation can be assumed to equal µ1k.
Often a more realistic starting point is a random effects meta-analysis where the
studies are assumed to be heterogenous. Then the true effect in study j can be modeled
with a hierarchical model
βkj ∼ N(βk, γ
2),
where γ2 describes the variability between the studies. Now estimate βˆkj in study j
differs then from βk because of both study heterogeneity and sampling error. The study
heterogeneity limits the impact a single study may have no matter how large the sample
size is (Sutton et al., 2007). However, if the interest still lies on parameter βk, adding
a layer for study heterogeneity does not change the problem definition: before the new
study our information is described as βk|D1 ∼ N(µ1k, σ
2
1k) and after the new study
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as βk | D1, D2 ∼ N(µ2k, σ
2
2k). Here again the expected µ2k can be assumed to equal
µ1k. Approximating σ
2
2k is a more difficult problem because of the study heterogeneity.
A simulation based solution is to generate results for the planned new study from the
predictive distribution and update the meta-analysis with the new study (Sutton et al.,
2007). Roloff et al. (2013) proposed a more straightforward approach to approximate
σ2
2k. Let v denote the within-study variance in the new study which can be estimated
on the basis of the within-study variances in the earlier studies. If the heterogeneity
for the new study is assumed to be equal to the earlier studies, the variance after the
new study can be approximated with
σ2
2k = σ
2
1k
v + γ2
v + γ2 + σ2
1k
. (3)
Ad hoc estimates for the overall heterogeneity exist for the cases where the new study is
expected to decrease or increase heterogeneity (Roloff et al., 2013). Informative priors
can be used in the cases where the heterogeneity cannot be reliably estimated because
of the small number of existing studies (Nikolakopoulou et al., 2016).
To summarize, the following simplifying assumptions and approximations are made
in the problem definition: the normality of the distributions, equality E(µ2k) = µ2k,
approximation of σ2k and the assumption that γ
2 will be unchanged in the new study.
The criteria that are presented in Section 3 are based on these assumptions and their
numeric values are sensitive e.g. to the changes in σ2k. However, it should be remem-
bered that covariate prioritization essentially means ranking the covariates and the
ranks are not likely to be very sensitive to the deviations from the assumptions.
2.2 Covariate prioritization in meta-analysis with sparse se-
lection priors
Above, it was assumed that the prior distribution is uninformative but in GWAS
a viable alternative is to use sparse selection priors (George and McCulloch, 1993;
O’Hara and Sillanpa¨a¨, 2009) as informative prior distributions. The sparseness means
that with a high probability, the effect is exactly zero. For the non-zero effects, a weakly
informative prior distribution is assumed. The collected data update our information
and the probability of a non-zero effect may increase.
The spike-and-slab prior (with point-mass at zero) can be defined hierarchically
and independently for each effect k as∏
k
p(βk|Ik)P (Ik),
where P (Ik = 1) = pi0 is a given small probability implying that most effects are
zero and non-zero effects are occurring only rarely. When data D1 are collected the
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inclusion probabilities are updated to P (Ik = 1 | D1) = pi1k. After stage 2, the inclusion
probabilities are further updated to P (Ik = 1 | D1, D2) = pi2k.
Conditional distribution p(βk|Ik) is defined as follows{
βk = 0, if Ik = 0,
βk ∼ N(µj, σ
2
j ), if Ik = 1,
(4)
where j = 0 before stage 1, j = 1 after stage 1 and j = 2 after stage 2.
Sparse selection priors can be seen as skeptical priors but in many cases they can be
used present realistic prior odds. Sparse selection priors are applied to meta-analysis
in the GWAS example considered in detail in Section 4.
3 Criteria for covariate prioritization
Next we will study several alternative criteria for the covariate prioritization by the
realized and expected scientific impact. The criteria can be used to classify the covari-
ates into categories I–III and to guide the decisions on the sample size. Out of the
seven criteria presented, conditional power has been considered earlier (Roloff et al.,
2013; Nikolakopoulou et al., 2014) but the six other criteria have not been used ear-
lier to measure scientific impact. The criteria represent different statistical principles
which arise from frequentist, information theoretic and Bayesian paradigms. For non-
Bayesian criteria, distributions (1) and (2) can be interpreted as representing a point
estimate and its asymptotic variance. The criteria are presented for the situation
where the studies in stage 1 have been carried out and the studies in stage 2 are to be
planned. Without the loss of generality it is assumed that the regression coefficients
are non-negative βk ≥ 0, k = 1, . . . , K.
3.1 Conditional power
The idea of conditional power is closely related to hypothesis testing or more pre-
cisely to the Neyman-Pearson decision theory. The conditional power is defined as the
power to reject the hypothesis βk = 0 after the new study is included in the meta-
analysis. A benchmark hypothesis is defined as βk = δk, where the smallest clinically
significant effect size δk (Copay et al., 2007; Revicki et al., 2008) is a known constant.
In general, the clinically significant effect size varies covariate by covariate and de-
pends on the measurement scale and the distribution of the covariate in the population
(Karvanen and Harrell Jr., 2009).
As a starting point, it is assumed that the meta-analysis of the earlier studies gives
inconclusive results, i.e. the hypothesis βk = 0 cannot be rejected on the basis of the
earlier studies. With significance level α, the conditional power can be calculated as
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(Roloff et al., 2013)
Φ

−Cα/2σ2k + µ1kσ1k√
1
σ2
2k
− 1
σ2
1k
+ δk
√
1
σ2
2k
−
1
σ2
1k

+
Φ

−Cα/2σ2k − µ1kσ1k√
1
σ2
2k
− 1
σ2
1k
− δk
√
1
σ2
2k
−
1
σ2
1k

 , (5)
where Cα/2 = Φ
−1(1 − α/2) is the 100(1 − α/2) percentile of the standard normal
distribution (1.96 for α = 0.05). The conditional power measures the expected scientific
impact in a straightforward manner: higher the power, higher the expected impact. In
the Neyman-Pearson framework, the realized scientific impact is a binary variable: the
hypothesis βk = 0 is either rejected or accepted after the new study.
The categorization presented in Introduction can be based on the conditional power.
The covariates for which the hypothesis βk = 0 can be rejected already before the new
study need not be studied further (category I). The division between category II and
category III can be made by defining a selection limit in the terms of the conditional
power. For instance, it could be required that the conditional power should be at
least 80%. The conditional power does not have a component for the importance of
the covariate but it is implicitly assumed that all covariates are equally important
regardless the value of βk.
3.2 Change of p-value
The use of p-values to prioritize covariates is closely related to Fisher’s null hypothesis
testing. It is well-known that the p-value of the null hypothesis βk = 0 does not alone
measure the relevance of a covariate because the p-value can be made arbitrarily small
by increasing the sample size. Therefore, the relevance must be decided comparing the
effect size with an external benchmark that does not depend on the data but is based
on expert knowledge. Let p1k be the p-value related to the null hypothesis βk = δk
before the new study and p2k < p1k be the p-value related to the same hypothesis after
the new study. The realized scientific impact can then be defined as
log(p1k)− log(p2k).
If p2k > p1k, the criterion is not applicable. The expected scientific impact is obtained
by calculating the expected p-value after the new study
log(p1k)− log(E(p2k)) =
log
(
2
(
1− Φ
(
µ1k − δk
σ1k
)))
− log
(
2
(
1− Φ
(
µ1k − δk
σ2k
)))
, (6)
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where Φ denotes the distribution function of the standard normal distribution. The
condition E(p2k) < p1k is fulfilled if µ1k > δk. The calculation utilizes the result
E(µ2k) = µ1k obtained from distribution (1). Strictly speaking this can be seen as a
violation against the frequentist principle that parameter βk is not random variable
but a fixed unknown quantity.
Similarly to conditional power, covariates for which p1k is below a pre-specified limit
can be classified into category I. The criterion gives a prioritization order for the rest
of the covariates. If µ1k < δk, the criterion implies that the covariate is a member
of category III and should not be studied further. This happens even if the current
estimate is based on a very small sample.
3.3 Change in lower confidence limit
Confidence intervals quantify the uncertainty of an estimate and can be also used to
measure the scientific impact. The main idea is to measure the distance from zero
to the lower confidence limit. Assume that the confidence interval for βˆk is (l1k, u1k)
before the new study and (l2k, u2k) after the new study. The realized scientific impact
can be measured by the change of the lower confidence limit
max(0, l2k)−max(0, l1k) =
max
(
0, σ2kΦ
−1(α/2) + µ2k
)
−max
(
0, σ1kΦ
−1(α/2) + µ1k
)
.
Utilizing the result E(µ2k) = µ1k, a criterion for the expected scientific impact can be
obtained
E(max(0, l2k))−max(0, l1k) =
max
(
0, σ2kΦ
−1(α/2) + µ1k
)
−max
(
0, σ1kΦ
−1(α/2) + µ1k
)
. (7)
The covariates for which l1k > δk can be classified into category I. The criterion ranks
the rest of the covariates.
3.4 Criterion based on Kullback-Leibler divergence
Kullback-Leibler divergence (Kullback and Leibler, 1951) is an information theoretic
quantity for the asymmetric distance of two distributions. A straightforward attempt to
quantify the scientific impact is to use the Kullback-Leibler divergence of the posterior
from the prior
K(fN (µ2k, σ
2
2k)||fN(µ1k, σ
2
1k)), which can be expressed in a closed form
K(fN(µ2k, σ
2
2k)||fN(µ1k, σ
2
1k)) =
∫
∞
−∞
log
fN (x | µ2k, σ
2
2k)
fN (x | µ1k, σ21k)
fN(x | µ2k, σ
2
2k)dx =
1
2
(
σ2
2k
σ2
1k
+
(µ2k − µ1k)
2
σ2
1k
− 1− log
σ2
2k
σ2
1k
)
.
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The expected Kullback-Leibler divergence is then given by
E[K(fN (µ2k, σ
2
2k)||fN(µ1k, σ
2
1k))] =∫
∞
0
∫
∞
−∞
1
2
(
σ2
2k
σ2
1k
+
(µ2k − µ1k)
2
σ2
1k
− 1− log
σ2
2k
σ2
1k
)
f(µ2k, σ
2
2k | µ1k, σ
2
1k)dµ2kdσ
2
2k =
−
1
2
−
1
2
log
σ2
2k
σ2
1k
+
σ2
2k
σ2
1k
,
where the last equality follows from the assumption µ2k ∼ N(µ1k, σ
2
2k) where σ
2
2k is
assumed to be known. It can be seen that the expected Kullback-Leibler divergence
depends only on the ratio of the variances. Therefore it is not a suitable criterion
as such for the expected scientific impact because after the sufficient precision of the
estimate has been achieved the additional decrease of variance does not have practical
relevance.
A more promising option is to use Kullback-Leibler divergence to quantify three
components: the improvement of the precision σ2
1k → σ
2
2k, the change of the mean
µ1k → µ2k and the clinical/practical importance of covariate k as a predictor. The
first two components describe the change in knowledge due to the new study and the
third component describes the importance of the problem. In this approach, we first
define an initial distribution N(0, σ2Ik) for βk where the variance σ
2
Ik is large to reflect
the lack of information on βk. Now the Kullback-Leibler divergence of the posterior
from the initial distribution measures the importance of the covariate. The difference
between the Kullback-Leibler divergence of the posterior from the initial distribution
and the Kullback-Leibler divergence of the prior from the initial distribution measures
the improvement of the precision and the change of the mean. To avoid the above
mentioned problem of irrelevantly small variance, the variances can be modified by
adding a positive term ω which bounds the importance of the variance. The realized
scientific impact can be then defined as
K(fN(µ2k, σ
2
2k + ω)||fN(0, σ
2
2k + ω))·(
K(fN(µ2k, σ
2
2k + ω)||fN(0, σ
2
Ik + ω))−K(fN (µ1k, σ
2
1k + ω)||fN(0, σ
2
Ik + ω))
)
.
The expected scientific impact can be approximated with
E(K(fN(µ2k, σ
2
2k + ω)||fN(0, σ
2
2k + ω)))·[
E(K(fN (µ2k, σ
2
2k + ω)||fN(0, σ
2
Ik + ω)))−K(fN(µ1k, σ
2
1k + ω)||fN(0, σ
2
Ik + ω))
]
=
1
4
(
µ2
1k + σ
2
1k
σ2
1k + ω
)(
2σ2
1k − σ
2
1k
σ2Ik + ω
− log
σ2
1k + ω
σ2
1k + ω
)
. (8)
The criterion ranks the covariates but does not give direct indication whether a covari-
ate belongs to category I. Some other criterion can be used first to identify covariates
that belong to category I.
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3.5 Difference between prior and posterior expectation
Bayesian criteria can be defined on the basis of the model with uninformative priors (2)
or the model with the sparse selection priors (4). We concentrate on the latter case
where the most of the effects are zero. This is often a reasonable assumption in genetics
and other fields where a massive number of potential covariates are tested.
When planning a new study, the posterior p(βk|D1, D2) is not known. The expected
posterior can be approximated by
σˆ2
2k =
1
1
σ2
1k
+ 1
σˆ2
Dk
µˆ2k = σˆ
2
2k
(
µ1k
σ2
1k
+
µˆDk
σˆ2Dk
)
(9)
pˆi2k =
pi1kfN ( ˆµDk | 0, σˆ
2
Dk)
pi1kfN(µˆDk | 0, σˆ
2
Dk) + (1− pi1k)fN (µˆDk | µˆ2k, σˆ
2
Dk)
,
where mean µˆDk and variance σˆ
2
Dk are related to the new study to be conducted.
Mean µˆDk is taken to be equal to the mean of the current data and variance σˆ
2
Dk is
approximated on the basis of the current data and the sample size of the new study.
We propose three Bayesian criteria to measure expected scientific impact. The first
criterion uses the difference between prior and posterior expectation
pˆi2kµˆ2k − pi1kµ1k (10)
as the measure. Here µ1k and µˆ2k measure the importance of the problem and pi1k and
pˆi2k measure the precision. The criterion ranks the covariates but does not give direct
indication if a covariate with a low value of the criterion belongs to category I or III.
This can be concluded using, for instance, Bayes factors presented next.
3.6 Change in Bayes factor
Commonly used Bayes factors (BF) have attractive properties as measures of evidence
and can be also utilized in measuring scientific impact. The evidence is combined from
multiple data sources (Ball, 2007; Wakefield, 2008) and similarly to likelihood ratio
statistic compared against a null model (Lee and Thomas, 2000). For each k, BF is
calculated as the posterior inclusion ratio divided by the prior inclusion ratio
BFk =
P (Ik = 1 | D1, D2)
P (Ik = 0 | D1, D2)
/P (Ik = 1 | D1)
P (Ik = 0 | D1)
. (11)
Jeffreys (1961) have provided following guidelines to make a formal decision based on
BFs between: 1 and 3 (barely worth mentioning), 3 and 10 (substantial support), 10
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and 100 (strong support), more than 100 (decisive support). With sparse selection
priors, the BF limits can be significantly larger.
BFs are useful in the interpretation of significant associations (Ioannidis, 2008) be-
cause the interpretation is independent from the sample size (unlike p-values) (Wakefield,
2009). However, assume that we already have collected lot of data and the prior proba-
bility P (Ik = 1 | D1) is close to one for given k. Now, the criterion for scientific impact
should tell that collecting more data may not change our knowledge. The direct usage
of BF fails to do this: when the posterior P (Ik = 0 | D1, D2) approaches to zero, the
criterion increases without bounds. Therefore, scientific impact should be measured
comparing BF before and after the new study. A covariate belongs to category I if the
BF before the new study is greater than the limit of decisive support and to category
III the expected BF after the new study is below this limit. If the new study is expected
to increase the BF so that it will exceed the limit, the covariate belongs to category II.
3.7 Criterion based on Bayesian false discovery rate
The third Bayesian criterion utilizes Bayesian false discovery rate (BFDR) control
approach (Ventrucci et al., 2011; Efron et al., 2001) separately for the distributions
before and after the new study. When the posteriors are considered, we approxi-
mate the local false discovery rate (LFDR) for each covariate k with the probability
P (Ik = 0 | D1, D2). Global level BFDR can then be calculated (at given probability
level) by combining these local quantities over the covariates. This is done by ordering
LFDRk = P (Ik = 0 | D1, D2) values to the ascending order and averaging the smallest
LFDRk values until the average is still smaller than given probability level (e.g., 0.05).
All covariates contributing to the average are then declared to be ‘significant’ or ‘in-
teresting’. Note that BFDR also contains multiplicity adjustment (Scott and Berger,
2010). When the distributions before the new study are considered, we repeat the same
procedure with the probabilities P (Ik = 0|D1). As an outcome, we have two sets of
covariates: one from the BFDR analysis before the new study and one from the BFDR
analysis after the new study. The covariates in the latter set but not in the former set
are considered as the covariates in category II.
4 Illustration: GWAS for CRP
In the illustrative example, the criteria presented in Section 3 are applied to guide the
design of new studies on genetic variants associated with CRP. The source code to
reproduce the results is available at
http://www.tilastotiede.fi/papers/Karvanen_Sillanpaa_GWAS_example.zip. As
a starting point, we consider a fixed-effects meta-analysis of GWAS in over 80,000 sub-
jects (Dehghan et al., 2011). In this meta-analysis, 17 loci were identified in a “discov-
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ery panel” of 15 studies and 66,185 participants. The identified 17 loci were studied
further in a “replication panel” of 10 studies and 16,540 participants. The 17 loci
are listed in Table 1 together with estimates from the replication panel. Evidence of
replication was provided for seven loci (Dehghan et al., 2011). In other words, there
were 10 loci for which the evidence of replication could not be provided. We use the
example only to demonstrate the covariate prioritization and do not discuss general
issues related to the analysis of GWAS replications (Ioannidis et al., 2001; Skol et al.,
2006; Sillanpa¨a¨ and Auranen, 2004).
Now the question of interest is the selection of loci for a new replication. For
this, we rank the loci according to the expected scientific impact measured by the
seven criteria presented in Section 3. The new replication is assumed to share the
essential characteristics with the original replication and to have the same sample size.
Dehghan et al. (2011) found that the between-study heterogeneity was statistically
significant in their meta-analysis but they do not report results from a random-effects
meta-analysis. Without the estimated between-study variances, we are compelled to
follow their example and to base our calculations on a fixed-effects meta-analysis. In
the illustration, we restrict to 17 loci in Table 1 although in practice it would be
reasonable to also consider other loci from GWAS when designing a new replication.
Parameter βk describes the effect of SNP k on the log-CRP in a linear model
(Dehghan et al., 2011). The user defined parameters for the criteria were set as follows.
On the basis of the results on the association of CRP and cardiovascular diseases
(Danesh et al., 2000; Pepys and Hirschfield, 2003), we set clinically significant effect
size for log-CRP to be δk = 0.03. This value was used for the change in p-value and
conditional power. Following the original report (Dehghan et al., 2011), significance
level α = 6.9 × 10−4 was selected for conditional power and for the change in lower
confidence level. Large initial variance σ2Ik = 100 and small variance limit ω = 0.01
2
were used for Kullback-Leibler divergence based criterion. For the Bayesian criteria,
we used the sparse selection priors presented in Section 2.2. We expected one SNP out
of a million to be associated with CRP and used prior inclusion probability pi0 = 10
−6
for all SNPs. Consistently with this prior, a limit of one million is used for BF. BFDR
we chose to be 0.05.
The results are presented in Table 1. The genes are ordered by their p-value in
the discovery panel. It is investigated which genes have the highest expected scientific
impact according to different criteria. It is seen that CRP, APOC1 and HNF1A can
be classified into category I by both frequentist and Bayesian criteria. All the criteria
rank the genes LEPR, IL6R and IL1F10 among the four top genes. The conditional
power is high also for GCKR. Change in p-value, change in lower confidence limit and
Kullback-Leibler divergence based criterion identify also SALL1 as a gene to be studied
further. Overall, the results are quite consistent, even between the frequentist and the
Bayesian criteria.
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Table 1: Application of covariate prioritization in design of a new replication study on genetic variants associated
with CRP. Effect sizes estimated from the discovery panel and from the replication panel are presented for the 17
loci that were associated with CRP in the discovery panel (Dehghan et al., 2011). Estimated β represents one-
unit change in the natural log-transformed CRP (mg/L) per copy increment in the coded allele. The frequentist
criteria measure the expected scientific impact for the new replication by conditional power (CP), change of p-
value (∆log(p)), change of lower confidence limit (LCL) and Kullback-Leibler (KL) criterion (8) multiplied by 1000.
∆ log(p) would be negative if β < δk and is not reported. A result with superscript
∗ indicates that the gene belongs
to category I. The Bayesian criteria include difference between prior and posterior expectation (10) ∆E(β) and BF
and BFDR analyses where 1–1 indicates category I, 1–0 indicates category II and 0–0 indicates category III. The
highest expected scientific impacts according to each criteria are bolded.
Gene SNP Discovery Replication Frequentist criteria Bayesian criteria
(coded allele) β (SE) β (SE) CP ∆log(p) LCL KL ∆E(β) BF BFDR
CRP rs2794520 (C) 0.193 (0.007) 0.086 (0.010) 1.00∗ 16.0∗ 0.010∗ 3570∗ 0.000∗ 1–1 1–1
APOC1 rs4420638 (A) 0.240 (0.010) 0.200 (0.032) 0.99∗ 14.4∗ 0.032∗ 10060∗ 0.001∗ 1–1 1–1
HNF1A rs1183910 (G) 0.152 (0.007) 0.122 (0.021) 0.99∗ 9.9∗ 0.021∗ 6168∗ 0.005∗ 1–1 1–1
LEPR rs4420065 (C) 0.111 (0.007) 0.045 (0.009) 1.00 1.6 0.009 931 0.035 1–0 1–0
IL6R rs4129267 (C) 0.094 (0.007) 0.045 (0.010) 1.00 1.4 0.010 995 0.044 1–0 1–0
GCKR rs1260326 (T) 0.089 (0.007) 0.031 (0.010) 0.90 0.0 0.007 485 0.000 0–0 0–0
NLRP3 rs12239046 (C) 0.048 (0.007) 0.042 (0.018) 0.21 0.4 0.000 885 0.000 0–0 0–0
IL1F10 rs6734238 (G) 0.047 (0.007) 0.072 (0.017) 0.89 3.3 0.017 2530 0.070 1–0 1–0
PPP1R3B rs9987289 (G) 0.079 (0.011) 0.003 (0.031) 0.00 – 0.000 127 0.000 0–0 0–0
ASCL1 rs10745954 (A) 0.043 (0.006) 0.018 (0.015) 0.05 – 0.000 218 0.000 0–0 0–0
HNF4A rs1800961 (C) 0.120 (0.018) 0.023 (0.026) 0.00 – 0.000 283 0.000 0–0 0–0
RORA rs340029 (T) 0.044 (0.007) 0.004 (0.010) 0.08 – 0.000 32 0.000 0–0 0–0
SALL1 rs10521222 (C) 0.110 (0.017) 0.089 (0.028) 0.29 2.5 0.022 2475 0.002 0–0 0–0
PABPC4 rs12037222 (A) 0.047 (0.008) 0.035 (0.017) 0.16 0.1 0.000 650 0.000 0–0 0–0
BCL7B rs13233571 (C) 0.054 (0.010) 0.049 (0.025) 0.05 0.5 0.000 927 0.000 0–0 0–0
PSMG1 rs2836878 (G) 0.040 (0.007) 0.013 (0.011) 0.19 – 0.000 114 0.000 0–0 0–0
RGS6 rs4903031 (G) 0.046 (0.008) 0.001 (0.012) 0.01 – 0.000 37 0.000 0–0 0–0
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The sensitivity to the choice of user defined parameters is studied in the Bayesian
setup where the prior probability of non-zero effect size is set to have a wide range
of values from 10−16 to 10−0.2. The results based on the BFDR analysis under these
settings are given in Figure 1. It can be seen that the selection of SNPs strongly
depends on the prior probability but there is a clear logic behind the results. When
the prior probability is small, most of SNPs are not selected because the additional
data would not be sufficient to change the conclusions (category III). When the prior
probability increases, the new study is expected to change the prior non-significance
to posterior significance (category II) and SNP becomes selected. When the prior
probability further increases, the evidence is sufficient even without the new study
(category I) and the SNP is not selected. Naturally, the prior must be the same for
both the design and the analysis. Thus, the question of the prior selection is not specific
for the covariate prioritization but common for Bayesian analysis in general.
To illustrate how the criteria can be used to guide the decisions on the sample
size we study the expected scientific impact as a function of the sample size of the
replication study. We measure the expected scientific impact by the difference between
prior and posterior expectation but the other criteria could be applied as well. The
results in Figure 2 can be used to conclude the sample size required to have a desired
expected scientific impact. For instance, the sample sizes below 14,000 seem to be
insufficient for gene SALL1. Increasing the sample size after a certain limit does not
bring benefits. For instance, increasing the sample size from 10,000 to 200,000 does not
increase the expected scientific impact for LEPR. The graph also tells that the gene
with the highest expected scientific impact is LEPR when the sample size is below
8300, then become IL6R and ILF10 and finally SALL1 when the sample size is above
33,000. These genes are the same as the top genes in Table 1.
5 Discussion
We have proposed that covariate prioritization should be based on a formal decision
criterion and have introduced a variety of new criteria to aid the study design in
situations where there already is previous knowledge. The prioritization is based on
the idea that the covariates in the category II should be preferred in replication studies.
The criteria can be also used to guide the decisions on the sample size. The example
on GWAS replication demonstrates the applicability of the proposed approaches in
covariate prioritization and sample size determination.
Each criterion defined in Section 3 requires some parameters to be specified. Guide-
lines exist for the specification of clinically significant effect size δk (Copay et al., 2007;
Revicki et al., 2008) as well as for the elicitation of experts’ opinions about prior dis-
tributions (O’Hagan et al., 2006). The selection by a formal criterion encourages the
researcher to express his or her preferences explicitly in a quantitative form. In addition
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Figure 1: Sensitivity of BFDR analysis as a function of prior probability of non-zero
effect size. The solid line indicates that the SNP should be included in the new repli-
cation analysis for the given prior probability. The dotted line indicates that it is
not necessary to include the SNP in the new replication analysis because the existing
results are already conclusive. The absence of a line indicates that the gene should
not be included in the replication because it is unlikely that a non-zero posterior effect
could be found in the meta-analysis after the new study.
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Figure 2: The impact of sample size of the new replication to expected scientific impact
measured by ∆E(β). The prior inclusion probability was set at pi00 = 10
−6. The genes
for which ∆E(β) < 0.01 even for sample size 200,000 are not displayed.
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to the presented criteria, other alternatives can be formulated. For instance, frequentist
false discovery rate (Benjamini and Hochberg, 1995) could be used in a similar manner
as BFDR in Section 3.5. Likewise, the overlapping coefficient (Inman and Bradley Jr,
1989) and Hellinger distance (Pollard, 2002) used by Nikolakopoulou et al. (2016) could
be also applied to covariate selection.
In some cases, the presented criteria may lead to different choices of covariates to be
studied. We recommend the researchers to use a criterion that is in agreement with the
statistical analysis to be carried out. For instance, conditional power is closely related
to the Neyman-Pearson type decision making and the Bayesian criteria are natural
choices with a Bayesian analysis. Sensitivity analyses similar to one in Figure 1 are
recommended for learning about the impact of the user defined parameters to the
prioritization.
In the presented example, it was realistic to assume that the marginal costs of
measurement are the same for all covariates. This assumption can be relaxed by first
calculating the affordable sample size for each covariate and then applying the formal
criterion with these sample sizes. It is also possible to extend the covariate prioritization
and sample size determination for the design of multiple studies.
In general, covariate prioritization using a formal criterion is expected to work best
in scenarios such as GWAS where a large number of covariates are used independently
from each other in the analysis. The approach may not be useful in scenarios the data
are modeled as a complex causal network between variables and confounding is a major
issue.
We hope that this work will encourage researchers to consider the study design in
a systematic way. As a benefit, researchers would be able to make smarter decisions
on the allocation of their time, effort and resources.
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